Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Receivables: 2021-2024

Historic Receivables for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $41.7 million.

  • Kiniksa Pharmaceuticals International's Receivables rose 107.90% to $51.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.4 million, marking a year-over-year increase of 100.29%. This contributed to the annual value of $41.7 million for FY2024, which is 96.20% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Receivables of $41.7 million as of FY2024, which was up 96.20% from $21.3 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's 5-year Receivables high stood at $41.7 million for FY2024, and its period low was $4.0 million during FY2021.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Receivables had a median value of $21.3 million in 2023 and averaged $27.8 million.
  • Data for Kiniksa Pharmaceuticals International's Receivables shows a peak YoY soared of 409.81% (in 2022) over the last 5 years.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's Receivables (Yearly) stood at $4.0 million in 2021, then surged by 409.81% to $20.3 million in 2022, then climbed by 4.68% to $21.3 million in 2023, then soared by 96.20% to $41.7 million in 2024.